These data confirm the effectiveness of TLF-II in mitigating inflammation during UTI episodes, with its anti-inflammatory mechanism likely exerted through the modulation of the TLR4-NF-κB pathway. Here, NFKB1 is linked to bacterial urinary tract infection.